




General description

Ceftriaxone is a third-generation cephalosporin.

| | |
|--------------------|---|
| INN | Ceftriaxone |
| ATC codes | J01DD04 |
| Medicine type | Chemical agent |
| Antibiotic groups |  WATCH |
| EML status history | <p>First added in 1995 (TRS 867) for Bacterial infection of unspecified site</p> <p>Added in 2017 (TRS 1006) for Bacterial meningitis</p> <p>Added in 2017 (TRS 1006) for Osteomyelitis or osteitis</p> <p>Added in 2017 (TRS 1006) for Bacterial infection of joint</p> <p>Added in 2017 (TRS 1006) for Sepsis without septic shock</p> <p>Added in 2017 (TRS 1006) for Infectious gastroenteritis or colitis without specification of infectious agent</p> <p>Added in 2017 (TRS 1006) for Gonococcal infection</p> <p>Added in 2017 (TRS 1006) for Peritoneal abscess</p> <p>Added in 2017 (TRS 1006) for Peritonitis</p> <p>Removed in 2017 (TRS 1006) for Bacterial infection of unspecified site</p> <p>Added in 2017 (TRS 1006) for Bacterial pneumonia</p> <p>Added in 2017 (TRS 1006) for Other specified pneumonia</p> <p>Added in 2017 (TRS 1006) for Acute pyelonephritis</p> <p>Added in 2017 (TRS 1006) for Inflammatory and other diseases of prostate</p> <p>Added in 2019 (TRS 1021) for Typhoid fever</p> <p>Added in 2019 (TRS 1021) for Paratyphoid fever</p> <p>Added in 2021 (TRS 1035) for Necrotising fasciitis</p> <p>Added in 2021 (TRS 1035) for Endophthalmitis</p> |
| Wikipedia | Ceftriaxone  |
| DrugBank | Ceftriaxone  |

Recommendations

Section Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Indications

First choice

Typhoid fever

Paratyphoid fever

Bacterial meningitis

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with [amikacin](#)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [amikacin](#)

Acute pyelonephritis (severe)

co-prescribed with [azithromycin](#)

Gonococcal infection

co-prescribed with [clarithromycin](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with [metronidazole](#)

Necrotising fasciitis

co-prescribed with [metronidazole](#)

Peritonitis (mild-moderate)

co-prescribed with [metronidazole](#)

Peritoneal abscess (severe)

co-prescribed with [metronidazole](#)

Peritonitis (severe)

co-prescribed with [metronidazole](#)

Peritoneal abscess (mild-moderate)

co-prescribed with [vancomycin](#)

Endophthalmitis

Second choice

Acute pyelonephritis (mild to moderate)

Inflammatory and other diseases of prostate (mild to moderate)

Sepsis without septic shock

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Other indications

Bacterial infection of unspecified site

